H.C. Wainwright & Co.

Cadrenal Raises $3M in Private Placement, Extends Runway to Q1 2027

PONTE VEDRA – – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) has agreed to raise $3 million in gross proceeds from a single healthcare-focused institutional investor. Warrants could bring in about $5.8 million more if exercised in full for cash.

Cadrenal prices 960,000 shares at $3.125 with two warrant series attached

The private placement covers 960,000 common shares, or pre-funded warrants in lieu, at a combined price of $3.125 per share with accompanying warrants. The deal is priced at-the-market under Nasdaq rules. Each unit carries series C-1 and series C-2 warrants, each series covering up to 960,000 shares at a $3.00 exercise price. H.C. Wainwright & Co. is exclusive placement agent. Closing is expected on or about July 1, 2026, subject to customary conditions.

MySize Raises $2.5M via Private Placement at $1.91/Share

MySize Raises $2.5M via Private Placement at $1.91/Share

Airport City, Israel – September 19, 2026 -- MySize, Inc. (NASDAQ: MYSZ) has signed definitive agreements to sell 1,308,901 shares of common stock, or pre-funded warrants in lieu thereof, at $1.91 per share, generating expected gross proceeds of approximately $2.5 million.

Private placement priced at-the-market carries dual warrant coverage

Alongside the common stock, MySize will issue unregistered Series C warrants for up to 1,308,901 shares and Series D warrants for up to 1,308,901 shares, both exercisable immediately at $1.66 per share. The Series C warrants run for five years from the effective date of the company's forthcoming resale registration statement, while the Series D warrants expire after 18 months from that same trigger date.